Ocean Biomedical (OCEA) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
Ocean Biomedical, Inc. (OCEA) is integrating ESG principles into the development of immune therapies, strictly adhering to bioethics and environmental safety. Management is focused on the commercial advancement of cutting-edge medical technologies in oncology. This EV/EBITDA price action chart on GURU.Markets captured a value of . Independence from global economic fluctuations and sustained interest in biopharmaceuticals make the asset a reliable defensive tool over the long term.
oceanbiomedical.com - analytical breakdowns and key metrics (OCEA)
- current price and projected stock value:
- market capitalization details:
- book value of equity indicators:
- debt level and financial liquidity data:
Debt to Equity Ocean Biomedical, Inc.|OCEA - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Ocean Biomedical|OCEA - Company Cumulative Debt|Debt to Book Capitalization Ratio Ocean Biomedical Corp|OCEA - Long-Term Debt|Company Short-Term Debts Ocean Biomedical|Quick Ratio oceanbiomedical.com
- business earnings and investment ratios data:
OCEA - Company Net Income|Projected Future Earnings Ocean Biomedical, Inc.|OCEA - P/E Multiple|Future Price to Earnings Ocean Biomedical, Inc.|OCEA - Growth-Adjusted P/E Ratio|Enterprise Value to EBITDA Ratio Ocean Biomedical Corp|OCEA - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Ocean Biomedical|OCEA - Earnings per share for the last twelve months|Quarterly EPS earnings growth oceanbiomedical.com|OCEA - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Ocean Biomedical, Inc.
Initial company analysis:OCEA (Ocean Bio)
Ocean Biomedical, Inc. (OCEA) employs a strategy of diversifying R&D risks through university collaborations, which necessitates strict control over its debt load. The EV/EBITDA metric measures the total enterprise value relative to operating profit before depreciation and amortization, revealing the model's resilience to cost inflation. By analyzing this EV/EBITDA chart, an investor can determine the asset's degree of overvaluation and the company's margin of safety amid high credit pressure.
Competitor analysis
EV/EBITDA Multiple ARGX (Argenx)|Total Company Value to Operating Income Before Depreciation Ratio BioNTech Pharma (BNTX)|ABVX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|admabiologics.com (ADMA) - Enterprise Value to EBITDA Ratio|Protagonist (PTGX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Immunovant Inc|Enterprise Value to EBITDA Ratio KNSA|EV/EBITDA Multiple Grifols Biemat|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Adaptive Biotechnologies (ADPT)|celldex.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple AUPH (Aurinia Pharmaceuticals Inc.)|BioCryst Pharmaceuticals, Inc. (BCRX) - Company Value to EBITDA|VERA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Dianthus Corp|PHVS: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio AbCellera|TRML (Tourmaline Bio) - EV/EBITDA Multiple|Company Value to EBITDA Precigen Inc PGEN|EV/EBITDA Multiple PHAR|EV/EBITDA Multiple Nektar Corp (NKTR)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Upstream Bio Inc UPB|ZBIO: Enterprise Value to Operating Income Before Depreciation|IMNM: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation GOSS (Gossamer Bio Inc)|KALV: EV/EBITDA Multiple|SEPN (Septerna Pharma) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PVLA (Pieris Pharmaceuticals) - EV/EBITDA Multiple|savarapharma.com (SVRA) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Rigel Pharmaceuticals, Inc. (RIGL)|ANAB - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Astria Pharma ATXS|ENGN - Enterprise Value to EBITDA Ratio|RAPT Therapeutics - EV/EBITDA Multiple|Company Value to EBITDA Aerovate Therapeutics Inc|ACRS: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation KYTX|TLSA (Tiziana Life Sciences PLC) - EV/EBITDA Multiple|Cabaletta Bio Inc (CABA) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple VTYX|Enterprise Value to EBITDA Ratio theratech.com THTX|EV/EBITDA Multiple AVTX (Avalo Therapeutics)|EV/EBITDA Multiple Eledon Pharmaceuticals Inc. ELDN|AGEN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CLYM: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ZURA (Zura Bio) - Enterprise Value to EBITDA Ratio|atyrpharma.com - Business Value to Operating Income Before Depreciation|ADAG (Adagene Inc) - EV/EBITDA Multiple|Ikena Oncology, Inc. (IMA) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Shattuck Labs, Inc. (STTK)|equilliumbio.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple CNTB (Connect Biopharma Holdings Limited)|IMUX - Enterprise Value to EBITDA Ratio|ATRA: Enterprise Value to EBITDA Ratio|Total Company Value to Operating Income Before Depreciation Ratio InflaRx N.V. IFRX|X4 Pharma (XFOR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Adicet Bio, Inc. (ACET)|CELU (Celularity Inc) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio inmunebio.com (INMB)|EV/EBITDA Multiple BRNS|KZR - Company Value to EBITDA|EV/EBITDA Multiple SABS (SAB Biotherapeutics, Inc)|EV/EBITDA Multiple Akari Therapeutics, Plc AKTX|ENLV - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio QTTB|GOVX: EV/EBITDA Multiple|Edesa Biotech Inc - Business Value to Operating Income Before Depreciation|IBIO (iBio Corp) - EV/EBITDA Multiple|EV/EBITDA Multiple Carisma Tx|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization XTL Biopharmaceuticals (XTLB)|BOLT (boltbio.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization HCW Biologics HCWB|APVO - Enterprise Value to EBITDA Ratio|AIM ImmunoTech Inc. - EV/EBITDA Multiple|ADTX - EV/EBITDA Multiple|GRI (GRI Bio, Inc.) - Enterprise Value to EBITDA Ratio|xortx.com - Business Value to Operating Income Before Depreciation|HIND (Vyome Holdings) - EV/EBITDA Multiple|Revelation Biosciences Inc (REVB) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Indaptus (INDP)|Enterprise Value to EBITDA Ratio BiondVax Pharmaceuticals SCNI|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CalciMedica CALI|AFMD - Enterprise Value to EBITDA Ratio|ALLK: Enterprise Value to EBITDA Ratio|HOOK - EV/EBITDA Multiple|igmbio.com (IGMS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation ITOS|TCBP (TC Biopharm) - EV/EBITDA Multiple|Company Value to EBITDA thirdharmonicbio.com THRD
